TickerFacts.

TScan Therapeutics, Inc. (TCRX): Long-Term Debt

Annual figures by period end, from SEC filings.

$32.53M
As of 2025-12-31
$32.78M
As of 2026-06-30
+3.6%
3-year compound annual growth
2022-12-31: $29.29M2023-12-31: $30.05M2024-12-31: $32.07M2025-12-31: $32.53M$32.53M
2022-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$32.53M+1.4%2026-03-04, Balance as of period end
2024-12-31$32.07M+6.7%2025-03-05, Balance as of period end
2023-12-31$30.05M+2.6%2024-03-06, Balance as of period end
2022-12-31$29.29Mn/a2023-03-08, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
TScan Therapeutics, Inc. (TCRX)2025-12-31$32.53M+1.4%
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Humacyte, Inc. (HUMA)2025-12-31$35.44Mn/a
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%

Compare TCRX, ALEC, XFOR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗